Literature DB >> 10684782

Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats.

A H Rezvani1, D H Overstreet, G A Mason, D S Janowsky, M Hamedi, E Clark, Y Yang.   

Abstract

It is common to treat some diseases with more than one medication simultaneously. Since more than one neurotransmitter system is involved in alcohol-seeking behaviour, then a therapeutic approach that targets more than one system should be more effective in reducing alcohol intake than one addressing a single system. To test this hypothesis, we compared the efficacy of low doses of individual drugs reported to reduce voluntary alcohol drinking to the efficacy of a mixture of these agents at the same low doses in reducing alcohol intake in three strains of alcohol-preferring rats (P, HAD, and Fawn-Hooded). After establishment of a stable baseline for alcohol intake in a continuous access paradigm, each rat received separate single i.p. injections of relatively low doses of either naltrexone (2.0 mg/kg), fluoxetine (1.0 mg/kg), the thyrotropin-releasing hormone analogue TA-0910 (0.2 mg/kg), a mixture of all three drugs, or the vehicle at 09:30. Each rat received all treatments, with an inter-injection washout period of at least 3 days. Alcohol and water intakes were measured at 6 and 24 h, and food intake was measured at 24 h, after the injection. Our results show that individual drugs did not significantly affect food, water, or alcohol intake. However, the mixture significantly reduced alcohol intake in all three strains, but had no effect on food intake. Similar results were obtained when the HAD rats received an oral dose of the individual drugs or the mixture. When P rats were given an i.p. injection of the mixture for 10 consecutive days, there was a continued suppressing effect. These findings show that a combination treatment designed to target simultaneously serotonergic, dopaminergic, and opioidergic systems can reduce alcohol intake, even though the doses of the individual drugs in the mixture are relatively low and ineffective when given singly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684782     DOI: 10.1093/alcalc/35.1.76

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  15 in total

1.  Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats.

Authors:  Amir H Rezvani; Susan Slade; Cori Wells; Ann Petro; Lawrence Lumeng; Ting-Kai Li; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Jed E Rose; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2010-06-10       Impact factor: 4.530

2.  Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.

Authors:  Jason E Gallate; Paul E Mallet; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

3.  Persistent high alcohol consumption in alcohol-preferring (P) rats results from a lack of normal aversion to alcohol.

Authors:  Amir H Rezvani; Hannah Sexton; Edward D Levin
Journal:  Alcohol Alcohol       Date:  2010-03-30       Impact factor: 2.826

Review 4.  Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date.

Authors:  Mary R Lee; Lorenzo Leggio
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 5.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

Review 6.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

7.  Prolonging the Reduction of Nicotine Self-Administration in Rats by Coadministering Chronic Nicotine With Amitifadine, a Triple Monoamine Reuptake Inhibitor With CYP2B6 Inhibitory Actions.

Authors:  Edward D Levin; Corinne Wells; Susan Slade; Michelle Lee; Anthony A McKinney; Jed E Rose; Amir H Rezvani
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

Review 8.  Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism.

Authors:  C Gianoulakis
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

Review 9.  Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism.

Authors:  Roberto Ciccocioppo; Daina Economidou; Andrea Cippitelli; Marino Cucculelli; Massimo Ubaldi; Laura Soverchia; Anbarasu Lourdusamy; Maurizio Massi
Journal:  Addict Biol       Date:  2006-09       Impact factor: 4.280

Review 10.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.